Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells

Cancer Research

Volumn 75, Issue 8, 2015, Pages 1691-1702

  Jang, Gyu Beom ^a   Hong, In Sun ^a   Kim, Ran Ju ^a   Lee, Su Youn ^a   Park, Se Jin ^a   Lee, Eun Sook ^b   Park, Jung Hyuck ^c   Yun, Chi Ho ^c   Chung, Jae Uk ^c   Lee, Kyoung June ^c   Lee, Hwa Yong ^d   Nam, Jeong Seok ^a  

^a Gachon University   (South Korea)

^b National Cancer Center   (South Korea)

^c Drug Discovery Center   (South Korea)

^d Jungwon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CWP 232228; DOCETAXEL; SOMATOMEDIN C; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; AZABICYCLO DERIVATIVE; CWP232228; MOLECULAR LIBRARY; ORGANOPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CELL FUNCTION; CELL NUCLEUS; CELL SPECIFICITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTRACELLULAR SIGNALING; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION TERMINATION; TREATMENT DURATION; TUMOR CELL; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME SPECIFICITY; MCF 7 CELL LINE; MOLECULAR LIBRARY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZABICYCLO COMPOUNDS; BETA CATENIN; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; ORGANOPHOSPHATES; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; WNT PROTEINS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938900150     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2041     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
2. Study quantifies risk of breast cancer recurrence. CA Cancer J Clin 2008;58: 322.
3. Visvader JE, Lindeman GJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012;10: 717-28.
4. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-9.
5. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444: 756-60.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-5.
7. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology 2008;1: 436-42.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100: 3983-8.
9. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20: 781-810.
10. Rask K, Nilsson A, BrannstromM, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: Increased expression of beta-catenin and GSK3beta. Br J Cancer 2003;89: 1298-304.
11. Kaler P, Godasi BN, Augenlicht L, Klampfer L. The NF-kappaB/AKTdependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron 2009;2: 69-80.
12. Zhang J, Li Y, Liu Q, Lu W, Bu G. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: Implication for breast cancer tumorigenesis. Oncogene 2010;29: 539-49.
13. Eaves CJ, Humphries RK. Acute myeloid leukemia and the Wnt pathway. N Engl J Med 2010;362: 2326-7.
14. Monteiro J, Gaspar C, Richer W, Franken PF, Sacchetti A, Joosten R, et al. Cancer stemness in Wnt-driven mammary tumorigenesis. Carcinogenesis 2014;35: 2-13.
15. Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP, Li L. Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 2008;180: 1087-100.
16. Biava PM, Nicolini A, Ferrari P, Carpi A, Sell S. A systemic approach to cancer treatment: Tumor cell reprogramming focused on endocrine-related cancers. Curr Med Chem 2014;21: 1072-81.
17. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 2012;142: 219-32.
18. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461: 614-20.
19. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5: 100-7.
20. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000;5: 95-105.
21. NamJS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68: 3915-23.
22. Choi AR, Park JR, Kim RJ, Kim SR, Cho SD, Jung JY, et al. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in amousemodel of breast cancer. Biochem Biophys Res Commun 2012;425: 436-42.
23. Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, et al. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 2006;66: 7176-84.
24. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicinbased chemotherapy for breast cancers. Clin Cancer Res 2009;15: 4234-41.
25. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
26. WellnerU, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemnessinhibiting microRNAs. Nat Cell Biol 2009;11: 1487-95.
27. Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 2013;25: 961-9.
28. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008;10: 1433-43.
29. Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 2013;73: 7290-300.
30. Kim RJ, Park JR, Roh KJ, Choi AR, Kim SR, Kim PH, et al. High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett 2013;333: 18-31.
31. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-13.
32. Galceran J, Hsu SC, Grosschedl R. Rescue of a Wnt mutation by an activated form of LEF-1: Regulation of maintenance but not initiation of Brachyury expression. Proc Natl Acad Sci U S A 2001;98: 8668-73.
33. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1: 555-67.
34. Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer 2012;118: 3225.
35. Paik S. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992;22: 31-8.
36. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3: 298-302.
37. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A. Breast cancer stem cells: A novel therapeutic target. Clin Breast Cancer 2013;13: 7-15.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144: 646-74.
39. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stemlike cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10: R25.
40. ZhangM, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006;16: 60-4.
41. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 2009;24: 385-98.
42. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, et al.Cytoplasmic localization of beta-catenin is amarker of poor outcomein breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010;19: 301-9.
43. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008;14: 4038-44.
44. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012;186: 1180-8.
45. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4: 505-18.
46. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26: 1636-44.
47. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010;10: 238.
48. Ye P, Hu Q, Liu H, Yan Y, D'Ercole A J. beta-catenin mediates insulin-like growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures. Glia 2010;58: 1031-41.
49. Wang L, Shao YY, Ballock RT. Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling. J Bone Miner Res 2010;25: 1138-46.
50. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/betacatenin signaling. PLoS Biol 2009;7: E1000121.